{"id":76338,"date":"2024-06-03T17:40:11","date_gmt":"2024-06-03T21:40:11","guid":{"rendered":"https:\/\/todaysveterinarybusiness.com\/?p=76338"},"modified":"2024-06-03T17:40:11","modified_gmt":"2024-06-03T21:40:11","slug":"fda-fip-treatment-060324","status":"publish","type":"post","link":"https:\/\/navc.sitepreview.app\/todaysveterinarybusiness.com\/fda-fip-treatment-060324\/","title":{"rendered":"FDA OKs Compounded Drugs in Certain FIP Cases"},"content":{"rendered":"

The U.S. Food and Drug Administration is allowing products compounded from the antiviral drug GS-441524 when they are prescribed by a veterinarian to treat some feline infectious peritonitis patients.<\/p>\n

The agency responded after Stokes Pharmacy announced that its compounded oral treatment for FIP would be available starting June 1.<\/p>\n

The FDA announcement also served to remind compounding pharmacies, veterinarians and pet owners that animal drugs compounded from bulk drug substances<\/a> are unapproved.<\/p>\n

\u201cHowever,\u201d the agency added, \u201cin Guidance for Industry (GFI) #256, the FDA has described certain conditions where the agency does not intend to take enforcement actions for compounded products for use in animals.\u201d<\/p>\n

According to the FDA, veterinarians who want to obtain animal drugs compounded from a bulk drug substance for office stock must nominate the bulk drug substance, including justification for its use.<\/p>\n

Stokes Pharmacy\u2019s compounded preparation is based on the Bova Group\u2019s drug formula, which is available from Bova Aus and Bova UK. The 50 mg tuna-flavored tablets are meant for the treatment of:<\/p>\n